Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 5,324 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Breast Cancer
Interventions: GDC-0927; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Germantown, Tennessee + 1 more

Conditions: Hypertension Secondary to Kidney Transplant
Interventions: New Medication: Enalapril, Isradipine, Propranolol; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 5 Years to 21 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Recurrent Glioblastoma Multiforme
Interventions: buparlisib, carboplatin, lomustine, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: TAK-881, Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US); Biological · Device
Lead sponsor: Takeda; Industry
Eligibility: 2 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: Irvine, California • Walnut Creek, California • Denver, Colorado + 10 more

Conditions: Obesity
Interventions: Control (bradykinin), L-NMMA + bradykinin, Isosorbide + L-NMMA + bradykinin, Sildenafil + L-NMMA + bradykinin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mantle Cell Lymphoma
Interventions: Bendamustine, Rituximab, Cytarabine, Pegfilgrastim, Leukapheresis, Filgrastim, Autologous stem cell transplant; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Smoking Cessation
Interventions: Ganaxolone, Nicotine Patch; Drug
Lead sponsor: Jed E. Rose; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more

Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Gamma-Secretase Inhibitor RO4929097, Hematopoietic Stem Cell Mobilization, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Melphalan; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Locally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer
Interventions: AZD1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee

Conditions: Ventricular Tachycardia, Ventricular Arrhythmias, Ventricular Fibrillation, Recurrent Ventricular Tachycardia
Interventions: Dexmedetomidine, Normal saline; Drug
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Kidney Stones
Interventions: cephalosporins, Fluoroquinolones, Clindamycin, Ampicillin/Gentamicin; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Manhasset, New York • New Hyde Park, New York

Conditions: Small Cell Lung Cancer
Interventions: Etoposide, Cisplatin, enoxaparin sodium; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 4
States / cities: Boston, Massachusetts • Peabody, Massachusetts

Conditions: Leukemia
Interventions: filgrastim, arsenic trioxide, cytarabine, idarubicin; Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 59 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Tourette's Disorder (TD)
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 38
States / cities: Anaheim, California • Riverside, California • Santa Ana, California + 30 more

Conditions: Leukemia, Myeloid, Acute
Interventions: glasdegib, daunorubicin + cytarabine, azacitidine, Placebo, cytarabine, HSCT; Drug · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 30
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 14 more

Conditions: Solitary Pulmonary Nodule, Multiple Pulmonary Nodules, Lung Neoplasms, Lung Cancer Screening
Interventions: Multiparametric chest MRI with diffusion-weighted imaging; Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 50 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions: Tremelimumab, Durvalumab, Radiation; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Takayasu's Arteritis, Giant Cell Arteritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 15 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 8
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: AZD4635, Oleclumab, Durvalumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 6 more

Conditions: Uveitis
Interventions: Mycophenolate mofetil, Methotrexate, Prednisone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Portland, Oregon

Conditions: Acute Myeloid Leukemia
Interventions: Atezolizumab, Hu5F9-G4; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Sacramento, California • New Haven, Connecticut • New York, New York + 1 more

Conditions: Peripheral Arterial Disease
Interventions: Pro-Omega, Pro-Omega Placebo; Dietary Supplement · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adenocarcinoma of the Prostate
Interventions: IMC-A12 (Cixutumumab); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: San Francisco, California • Portland, Oregon • Seattle, Washington

Conditions: Ewing's Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma
Interventions: pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex; Biological
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Search by objective public record fields.

A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Multiparametric Lung MRI With Diffusion-Weighted Imaging in Lung-RADS 4 Lesion Characterization

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Methotrexate and Mycophenolate Mofetil for UVEITIS

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma